Continuous jejunal infusion of levodopa–carbidopa intestinal gel (LCIG) provides a viable option to patients with advanced Parkinson’s disease (PD) who experience motor complications that are inadequately controlled by standard oral therapy.

Pharmacokinetic and efficacy benefits of continuous jejunal infusion of LCIG have been previously demonstrated in Western patients.

This study demonstrates that LCIG jejunal infusion results in lower fluctuations in levodopa concentrations and shows comparable bioavailability to oral administration in Japanese subjects with advanced PD. The improved pharmacokinetic profile with LCIG infusion appears to be associated with reduced motor complications.